Guggenheim Initiates Buy on Cullinan Therapeutics with $30 Target
Guggenheim starts coverage on Cullinan Therapeutics with a Buy rating, citing promising Phase 1 data for T-cell engagers in autoimmune diseases and AML.
/ 2 items
Guggenheim starts coverage on Cullinan Therapeutics with a Buy rating, citing promising Phase 1 data for T-cell engagers in autoimmune diseases and AML.
Cullinan Therapeutics (CGEM) receives FDA Fast Track designation for CLN-049, a novel therapy showing promising results in treating relapsed acute myeloid leukemia patients.